Key facts
- Attovia Therapeutics is a biopharmaceutical company.
- Goldman Sachs is a backer of Attovia Therapeutics.
- Attovia Therapeutics is planning an initial public offering (IPO).
- The company is targeting a valuation of $731.5 million.
- Attovia Therapeutics aims to raise $289 million through the IPO.
- The company will offer 17 million shares.
- The offering price for each share is $17.
Attovia Therapeutics, a biopharmaceutical company with backing from Goldman Sachs, is preparing for an upsized initial public offering (IPO). The company is targeting a valuation of $731.5 million as it seeks to raise $289 million. This fundraising goal will be achieved through the offering of 17 million shares, with each share priced at $17. The upsized nature of the offering suggests strong demand and confidence from investors in Attovia's potential within the competitive biopharmaceutical market. The company's focus on developing new therapies positions it for potential growth, and the IPO will provide the necessary capital to advance its pipeline and operations. The pricing of the shares at $17 each reflects a careful assessment of market conditions and the company's intrinsic value.